Pharmacokinetic and pharmacodynamic surrogate markers: Studies with fluoroquinolones in patients

American Journal of Health-System Pharmacy

Volumn 56, Issue 22 SUPPL. 3, 1999, Pages

  Schentag, Jerome J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

Clinical studies; Dosage; Methodology; Models; Pharmacodynamics; Pharmacokinetics; Pneumonia; Quinolones

Indexed keywords

GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0033571423     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.suppl_3.s21     Document Type: Conference Paper

References (26)

1. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986; 108:835-40.
2. Shah PM, Junghanns, Stille W. Dosis-wirkungs-beziehung der bakterizidie bei E.coli, K. pneumoniae und Staphylococcus aureus. [Bactericidal dose-activity relationships with E. coli, K. pneumoniae and Staph. aureus]. Dtsch Med Wochenschr. 1976; 101:325-8.
3. Nix DE, Schentag JJ. The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 1988; 28:169-78.
4. Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther. 1999; 21:3-42.
5. Schentag JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet. 1989; 16(suppl 1):25-31.
6. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother. 1997; 9(suppl 3):38-44.
7. Hyatt JM, McKinnon PS, Zimmer GS et al. The importance of pharmacokinetic/pharmacodynamic surrogate markets to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995; 28:143-60.
8. Luzier A, Goss TF, Cumbo TJ et al. Mathematical examination of dual individualization principles (III): development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients. Ann Pharmacother. 1992; 26:1358-65.
9. Hyatt JM, Luzier AB, Forrest A et al. Modeling the response of pneumonia to antimicrobial therapy. Antimicrob Agents Chemother. 1997; 41:1269-74.
10. Schentag JJ, Birmingham MC, Paladino JA et al. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Semin Respir Infect. 1997; 12:278-93.
11. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-10.
12. Donowitz GR, Mandell GL. Acute pneumonia. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995:619-38.
13. Forrest A, Ballow CH, Nix DE et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993; 37:1065-72.
14. Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimize antibiotic effects. Drug Invest. 1993; 5:256-68.
15. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37:1073-81.
16. Nix DE, Tyrrell R, Muller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother. 1995; 39:1848-52.
17. Nix DE, Schentag JJ. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Diagn Microbiol Infect Dis. 1995; 22:71-6.
18. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother. 1991; 25:1050-7.
19. Goss TF, Forrest A, Nix DE et al. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother. 1994; 28:863-8.
20. Doern GV, Pfaller MA, Erwin ME et al. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 1998; 32:313-6.
21. Doern GV, Jones RN, Pfaller MA et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother. 1999; 43:385-9.
22. Jones RN, Biedenbach DJ, Erwin ME et al. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J Clin Microbiol. 1999; 37:1999-2002.
23. Thornsberry C, Ogilvie P, Kahn J et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis. 1997; 29:249-57.
24. Lacy MK, Lu W, Xu X et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999; 43:672-7.
25. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42:521-7.
26. Schentag JJ, Nix DE, Forrest A et al. AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother. 1996; 30:1029-31.